The global drug and gene delivery devices market size is expected to reach around US$ 815 billion by 2030 from US$ 410 billion in 2021 and is expected to grow at an impressive double-digit rate of 7.2% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global drug and gene delivery devices market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
The global drug and gene delivery devices market is primarily driven by the rising prevalence of various chronic diseases such as cancer, diabetes, and cardiovascular diseases among the global population. The rapid growth of the biopharmaceuticals industry resulted in the development of various therapeutics and gene therapeutics that can effectively treat various chronic diseases and genetic diseases. The rising adoption of such drugs among the population is boosting the growth of the global drug and gene delivery devices market.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1388
Furthermore, the rising investments by the market players in the research and development of the drug delivery systems are fostering the market growth. The technological advancements are providing easy to use and convenient administration of drugs through various roots, which is expected to drive the drug and gene delivery devices market across the globe.
North America dominated the global drug and gene delivery devices market in 2020. The increased number of patients suffering from chronic diseases in the US has fostered the market growth in the region. According to a study, around 60% of the US population is suffering from at least one chronic diseases. Furthermore, the higher adoption rate of technologically advanced and innovative therapeutics among the North American population is spurring the demand for the drug and gene delivery devices. The rapidly growing biopharmaceutical industry is another significant driver of the market.
Asia Pacific is estimated to be the fastest-growing market during the forecast period. The presence of several top biopharmaceutical companies in the nations like India, China, and South Korea is propelling the market growth. The presence of huge population and rising prevalence of chronic diseases among the population is a major factor that is expected to drive the growth of the drug and gene delivery devices market in the region. Furthermore, the rising popularity of the personalized medicines among the population to treat genetic disorder may have a positive impact on the market. The rapid industrialization in the region is resulting in pollution that further propels the number of respiratory diseases among the population. Therefore, the rising number of disease due to the rising pollution levels in the region is expected to offer lucrative growth opportunities to the market players in the upcoming future.
The rising number of approvals for the newly developed therapeutics across the globe is expected to have a positive impact on the market. The major approving authorities such as FDA and EMA are very much active in monitoring the clinical trials of various medicines and diagnostic methods.
The stringent government regulations pertaining the drug and gene delivery devices and the infections and injuries caused by the injectable are the two major restraining factors that may hamper the growth of the global drug and gene delivery devices market during the forecast period.
Based on the delivery type, the injectable is estimated to be the most opportunistic segment during the forecast period. This can be attributed to the development and rising popularity of various injectable such as pen-injectors, self-injectors, and auto-injectors that emerged as a result of the technological advancements in the market. The rising number of diabetic population who needs to inject insulin as a diabetes management measure is expected to drive the growth of this segment. Moreover, the convenience associated with the injectable may boost the adoption of the injectable in the forthcoming years.
Based on the method, the in situ segment dominated the market in 2020. This can be attributed to the certain advantages associated with the in situ method such as low complication in fabrication and ease of drug administration. Moreover, the majority of the drugs that are currently used follows the in situ method.
Based on the vector, the viral vector segment dominated the market in 2020. This is due to the increased usage of the viral vectors for the majority of the clinical trials. Moreover, the rising prevalence of genetic disorders and chronic diseases among the global population is further fueling the segment growth. The extensive use of the viral vectors in the development of drugs and gene therapies has significantly contributed towards the growth of the segment in the past.
Why should you invest in this report?
If you are aiming to enter the global drug and gene delivery devices market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug and gene delivery devices are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global drug and gene delivery devices market include:
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd
- Johnson and Johnson Private Ltd
- Novartis AG
- Bayer AG
- Becton, Dickinson and Company
- Uniqure NV
Market Segmentation:
By Delivery Type
- Oral
- Ocular
- Inhalation
- Nasal
- Injectable
- Transdermal
- Topical
By Method
- In Situ
- Ex Vivo
By Vector
- Viral Vector
- Non-Viral Vector
Regional Analysis:
The geographical analysis of the global drug and gene delivery devices market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global drug and gene delivery devices Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global drug and gene delivery devices market in 2030?
- What is the expected CAGR for the drug and gene delivery devices market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global drug and gene delivery devices market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug and Gene Delivery Devices Market
5.1. COVID-19 Landscape: Drug and Gene Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug and Gene Delivery Devices Market, By Delivery
8.1. Drug and Gene Delivery Devices Market, by Delivery Type, 2021-2030
8.1.1. Oral
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Ocular
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Inhalation
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Nasal
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Injectable
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Transdermal
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Topical
8.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug and Gene Delivery Devices Market, By Method
9.1. Drug and Gene Delivery Devices Market, by Method, 2021-2030
9.1.1. In Situ
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Ex Vivo
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug and Gene Delivery Devices Market, By Vector
10.1. Drug and Gene Delivery Devices Market, by Vector, 2021-2030
10.1.1. Viral Vector
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Non-Viral Vector
10.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Drug and Gene Delivery Devices Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.1.2. Market Revenue and Forecast, by Method (2019-2030)
11.1.3. Market Revenue and Forecast, by Vector (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Vector (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.2.2. Market Revenue and Forecast, by Method (2019-2030)
11.2.3. Market Revenue and Forecast, by Vector (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Vector (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Method (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Vector (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Method (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Vector (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.3.2. Market Revenue and Forecast, by Method (2019-2030)
11.3.3. Market Revenue and Forecast, by Vector (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Vector (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Method (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Vector (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Method (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Vector (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Vector (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Method (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Vector (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Method (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Vector (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.5.3. Market Revenue and Forecast, by Vector (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Method (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Vector (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Method (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Vector (2019-2030)
Chapter 12. Company Profiles
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson and Johnson Private Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Becton, Dickinson and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Uniqure NV
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1388
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments